Industry experts from Insight Biosciences, AbbVie, GSK, and IQVIA discuss the latest PMPRB guidelines and their potential impact on drug pricing, market access, and healthcare innovation in Canada.

Key Topics:
– PMPRB’s evolving regulatory approach
– Potential effects on drug launches and R&D investments
– Strategies for pharmaceutical manufacturers
– Balancing drug pricing and patient access

Featuring insights from:
– Lauren Fischer (AbbVie)
– Ryan Locke (GSK)
-Joan McCormick (IQVIA)